首页|EBV miR-BART17-3p对原发免疫性血小板减少症患儿Treg/Th17平衡的影响

EBV miR-BART17-3p对原发免疫性血小板减少症患儿Treg/Th17平衡的影响

扫码查看
目的 探讨EBV miR-BART17-3p影响原发免疫性血小板减少症(ITP)患儿Treg/Th17 平衡的机制。方法 收集ITP患儿(ITP组,20 例)和健康儿童(对照组,20 例)外周血并分离CD4+T细胞。采用实时荧光定量聚合酶链式反应法、Western blot法、酶联免疫吸附法检测EBV miR-BART17-3p、T细胞免疫球蛋白黏蛋白 3(Tim-3)、叉头框蛋白P3(FoxP3)、白细胞介素 17A(IL-17A)和转化生长因子-β(TGF-β)的mRNA、蛋白表达水平及含量。采用双荧光素酶报告基因实验考察EBV miR-BART17-3p对Tim-3表达水平的影响。将 15 只BALB/C小鼠随机分为空白对照组、模型组、观察组,各 5 只。腹腔注射抗血小板抗体MWReg30 以复制ITP小鼠模型,建模 4d后观察组小鼠予尾静脉注射携带EBV miR-BART17-3p inhibitor的腺病毒载体。细胞染色并观察形态,检测外周血中TGF-β、IL-17A含量及血小板计数,采用流式细胞仪分别检测CD4+T细胞中Th17 和Treg水平,并计算二者百分比。结果 与对照组比较,ITP组患儿外周血EBV miR-BART17-3p表达水平显著升高,Tim-3 和TGF-β mRNA表达水平显著降低(P<0。05);Tim-3 mRNA表达水平与EBV miR-BART17-3p表达水平呈显著负相关(r=-0。732,P<0。001)。Tim-3 慢病毒载体pLKO。1-sh-Tim-3(sh-Tim-3)可显著降低Tim-3、FoxP3、TGF-β水平(P<0。05)。miR-BART17-3p mimic显著升高了CD4+T细胞中miR-BART17-3p的表达水平,并显著降低了Tim-3、FoxP3、TGF-β mRNA和蛋白表达水平(P<0。05);miR-BART17-3p mimic可显著降低TGF-β含量,Tim-3+miR-BART17-3p过表达逆转了miR-BART17-3p mimic对TGF-β的抑制作用。动物实验结果显示,沉默EBV miR-BART17-3p可促进Treg分化,减少脾脏和骨髓组织中的巨核细胞计数,并显著增加外周血中血小板计数。结论 EBV miR-BART17-3p可通过FoxP3/Tim-3 途径调节ITP患儿Treg/Th17 的免疫失衡。
Effect of EBV miR-BART17-3p on Treg/Th17 Balance in Children with Primary Immune Thrombocytopenia
Objective To investigate the mechanism of EBV miR-BART17-3p affecting the Treg/Th17 balance in children with primary immune thrombocytopenia(ITP).Methods The peripheral blood from ITP children(ITP group,20 cases)and healthy children(control group,20 cases)was collected and the CD4+T cells were isolated.The real-time fluorescence quantitative polymerase chain reaction,Western blot,and enzyme-linked immunosorbent assay were used to detect the mRNA,protein expression levels and contents of EBV miR-BART17-3p,T cell immunoglobulin domain and mucin domain-3(Tim-3),forkhead box protein P3(FoxP3),interleukin-17A(IL-17A),and transforming growth factor-β(TGF-β).The dual-luciferase reporter gene assay was used to explore the effect of EBV miR-BART17-3p on the expression level of Tim-3.Fifteen BALB/C mice were randomly divided into the blank control group,the model group and the observation group,with five mice in each group.Mice were intraperitoneally injected with antiplatelet antibody MWReg30 to construct the ITP models.After 4 d of modeling,the mice in the observation group were injected with adenovirus vector carrying EBV miR-BART17-3p inhibitor via the tail vein.Cells were stained for morphological observation;the TGF-β,IL-17A contents and platelet count in peripheral blood were detected;the flow cytometry was used to measure the Th17 and Treg levels in CD4+T cells,and their percentage was calculated.Results Compared with those in the control group,the expression level of EBV miR-BART17-3p in peripheral blood in the ITP group significantly increased,while the expression levels of Tim-3 and TGF-β mRNA significantly decreased(P<0.05);the expression level of Tim-3 mRNA was significantly negatively correlated with the expression level of EBV miR-BART17-3p(r=-0.732,P<0.001).Tim-3 lentivirus vector carrying pLKO.1-sh-Tim-3(sh-Tim-3)could significantly decrease the Tim-3,FoxP3 and TGF-β levels(P<0.05).The miR-BART17-3p mimic significantly increased the expression levels of miR-BART17-3p in CD4+T cells,and significantly decreased the mRNA and protein expression levels of Tim-3,FoxP3,and TGF-β(P<0.05);the miR-BART17-3p mimic could significantly decrease the TGF-β content,and the overexpression of Tim-3+miR-BART17-3p reversed the inhibitory effect of miR-BART17-3p mimic on the TGF-β.The animal experiment showed that silencing EBV miR-BART17-3p could promote the Treg differentiation and decrease the megakaryocyte count in spleen and bone marrow tissues,and significantly increase the platelet count in peripheral blood.Conclusion EBV miR-BART17-3p can regulate the immune imbalance of Treg/Th17 in ITP children through the FoxP3/Tim-3 pathway.

EBV miR-BART17-3pT cell immunoglobulin domain and mucin domain-3forkhead box protein P3helper T cell 17primary immune thrombocytopenia

张雅丽、闫雪峰、冯茹清

展开 >

河北省张家口市妇幼保健院,河北 张家口 075000

EBV miR-BART17-3p T细胞免疫球蛋白黏蛋白 3 叉头框蛋白P3 辅助性T细胞 17 原发性血小板减少症

河北省张家口市重点研发计划项目

1921068D

2024

中国药业
重庆市食品药品监督管理局

中国药业

CSTPCD
影响因子:1.369
ISSN:1006-4931
年,卷(期):2024.33(18)